fda import alert semaglutide tirzepatide green list launches 'green list' to block unsafe imported GLP-1 drug ingredients Last month, the FDA issued

Many cases can be managed with medications or hormonal therapies

GLP-1 RAs effectively reduce appetite and caloric intake, yet unstructured reduced dietary intake is often nutrient poor and patients risk losing the fiber, polyphenols, and foods that sustain microbiome diversity, normobiosis, microbial mediators, and intestinal barrier function

Takeaway The vision is for real-world patients on each of these drugs to be followed over the next two to four years to see what happens to their cardiac risk scores, and how that relates to their body mass index or other comorbidities

Less than 1 out of 100 experienced pancreatitis

2023 ODS umbrella review corroborates insulin resistance across 41 RCTs

Stopping the GLP-1 or cutting down the dose will usually improve it. The overall risk also seems to be low